Form 4: Aurinia Pharmaceuticals Director Craig Johnson Acquires Shares and Options

Director Craig Johnson of Aurinia Pharmaceuticals acquired 20,631 restricted stock units and 31,688 stock options on November 21, 2024.

Summary

• Craig Johnson, a director at Aurinia Pharmaceuticals, reported acquiring 20,631 restricted stock units (RSUs) and 31,688 stock options on November 21, 2024.
• The RSUs are payable in common shares of the company and will vest one year from the grant date.
• The stock options, which have an exercise price of $8.24, also vest one year from the grant date and expire on November 21, 2034.
• Both the RSUs and stock options were acquired directly by Mr. Johnson.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, which is generally positive as it shows director engagement and alignment with company performance. However, it is not a major event that would significantly impact sentiment.

Positives

• The acquisition of shares and options by a director may signal confidence in the company's future prospects.
• The vesting period of one year for both RSUs and options aligns with long-term value creation.

Risks

• There are no specific risks mentioned in this document, but the value of the acquired securities is subject to market fluctuations.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• The granting of stock options and restricted stock units to directors is a common practice in the pharmaceutical industry to align their interests with those of shareholders.
• The vesting period of one year is also typical for such grants.
• Companies like Biogen, Gilead Sciences, and Vertex Pharmaceuticals also use similar compensation methods for their directors and executives.

Stakeholder Impact

• The acquisition of shares and options by a director may be viewed positively by shareholders as it indicates confidence in the company's future.

Key Dates

Keywords

Aurinia Pharmaceuticals, Director, Craig Johnson, Stock Options, Restricted Stock Units, RSUs, Share Acquisition, Insider Trading